neurooncology

neu·ro·on·col·o·gy

(nū'rō-on-kol'ŏ-jē),
The branch of medicine concerned with the direct and indirect effects of neoplasms on the nervous system, neuromuscular junction, and muscle.
[neuro- + onco- + G. logos, study]

neu·ro·on·col·o·gy

(nūr'ō-on-kol'ŏ-jē)
The branch of medicine concerned with the direct and indirect effects of neoplasms on the nervous system, neuromuscular junction, and muscle.
[neuro- + onco- + G. logos, study]
Mentioned in ?
References in periodicals archive ?
Findings presented at the European Organization for Research & Treatment of Cancer (EORTC), European Association of NeuroOncology (EANO) and European Society for Medical Oncology (ESM0) congress in Istanbul demonstrate that EDO-S101 is effective in models of human glioblastoma irrespective of methyltransferase (MGMT) status and in combination with radiotherapy (RT).
The symposium also comprised parallel sessions on colorectal malignancies, genitourinary and gynaecological malignancies and neurooncology.
Prof Gumbleton has teamed up with Professor Geoff Pilkington from Portsmouth University, an internationally recognised and highly regarded scientist in the field of neurooncology.
From the Texas A&M College of Medicine (Reddy) and the Departments of Diagnostic Radiology (Saad, Opatowsky), Neurosurgery (Doughty), Pathology (Armstrong), Neurooncology (Melguizo-Gavilanes), and Radiation Oncology (Cheek), Baylor University Medical Center at Dallas.
Cellular and Molecular Neurooncology at the University of Portsmouth, who directs work funded by the charity Brain Tumour Research, says: "There are in excess of 120 different types of brain tumour and there are three major types.
Family flowers only please but donations to CANTAB, The Neurooncology Research Fund at University Hospital, Coventry (Walsgrave) via the family.
Currently, the most common molecular markers in neurooncology are 1p/19q codeletion in oligodendroglial tumors, mutations in the IDH1/2 genes in diffuse gliomas, hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter in glioblastomas and anaplastic gliomas, alterations in the EGFR and PTEN genes, and 10q deletions in GBMs, as well as BRAF alterations in pilocytic astrocytomas.
This study was presented at the Society for NeuroOncology Annual Scientific Meeting and Education Day in Montreal on Nov.
Martin Glas from the Department of Neurology's Clinical Neurooncology Unit explained.
So neurooncology wards as well as radio stations are on their itinerary.
11) A Besson and VW Yong, 'Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas', Journal of Neurooncology, vol.